MedTrace Logo

The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma

NCT06150144 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-01-02

No results posted yet for this study

Summary

The investigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.

Conditions

Interventions

DRUG

5-Fluorouracil

The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.

OTHER

SURGERY

Total excision of the lesion

Sponsors & Collaborators

  • Aleppo University Hospital

    collaborator UNKNOWN

  • University of Aleppo

    lead OTHER

Principal Investigators

  • Noura Abdulrahman, M.D. · Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria

  • Rama Haj mharram, M.D. · Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria

  • Ahmad Yamen Arnaout, M.D. · Faculty of Medicine, University of Aleppo, Aleppo, Syria.

  • Silva Ishkhanian, PhD · Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-25
Primary Completion
2025-05-25
Completion
2025-05-25

Countries

  • Syria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06150144 on ClinicalTrials.gov